Swiss agree to extradite Chinese researcher in US corporate espionage case
The case has exacerbated global fears that China is using networks of highly trained nationals abroad to gain trade secrets,
swissinfo.ch
This content was published on
2 minutes
The Swiss Federal Office of Justice (FOJ)External link has approved the extradition of a Chinese researcher to the United States. Gongda Xue is charged with using trade secrets stolen from a factory of the British pharmaceutical group GlaxoSmithKline (GSK).
The decision was taken on July 12, from which date the researcher has 30 days to appeal to the Federal Criminal Court, a spokeswoman for the FOJ told the French news agency, AFP, on Tuesday.
Gongda Xue is the brother of Yu Xue, a Chinese-American biochemist who pleaded guilty last year at a US District Court in Pennsylvania to stealing trade secrets on GSK’s work in the biopharmaceutical sector, including the treatment of cancer and other serious diseases.
A total of five people were charged in the case, three of whom formed a company in China called Renopharma to sell the stolen trade secrets.
Yu Xue, who worked for GSK from 2006 to 2016, had been presented by the American courts as one of the “leading protein biochemists in the world”.
According to a spokeswoman for the Friedrich Miescher Institute for Biomedical Research, Gongda Xue worked there “as a postdoctoral fellow from 2008 to 2014”.
The US Department of Justice last year called the case an “economic war”, claiming that Renopharma, based in Nanjing, China, is “financed by the Chinese government”.
Related Stories
Popular Stories
More
Swiss Politics
Will Switzerland finally do away with imputed rental-value tax on homeowners?
12,000 fish to be transferred by helicopter in Swiss river cleanup operation
This content was published on
Some 12,000 fish are being removed from the River Spöl in the Swiss National Park. This operation is necessary before cleaning up the riverbed, which was contaminated by PCBs during maintenance work in 2016.
Swiss parliament approves due diligence for high-risk consultancy activities
This content was published on
On Thursday, the House of Representatives accepted the draft of the Senate, which was largely watered down compared to the government's original proposal.
Zurich Film Festival will show 114 films and honour Russell Crowe
This content was published on
The 21st Zurich Film Festival (ZFF) will screen 114 films, including 16 Swiss productions and 41 European or world premieres, from 25 September to 5 October. Actor Russell Crowe will receive an honorary lifetime achievement award.
Emergency financial aid authorised for Swiss village buried by landslide
This content was published on
The Valais Grand Council gives the green light for a solidarity contribution of CHF 10 million for the village of Blatten, which was destroyed by the landslide. The aid is to benefit the population, companies and associations.
New attempt to regulate assisted suicide in Switzerland fails
This content was published on
Assisted suicide will not be regulated in Switzerland. On Thursday, the Senate rejected a motion from its Legal Affairs Committee.
Risk of sepsis is underestimated in Switzerland, warn experts
This content was published on
In Switzerland, over 20,000 people are hospitalised with sepsis every year. Around 4,000 die as a result, as a new report from the Swiss Sepsis Programme shows.
Swiss SME sentiment remains stable despite steep US tariffs
This content was published on
Despite the high US tariffs, the mood among Swiss SMEs has hardly deteriorated. However, two thirds of export-oriented companies have now adjusted their export strategy, with one in ten even questioning it as a whole.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss firms in record number of mergers and acquisitions
This content was published on
The number of merger and acquisition deals involving Swiss companies hit a record high in 2018, according to a report by consultancy firm KPMG.
This content was published on
In recent days, Johnson & Johnson has been urged to review its sprawling portfolio that ranges from baby oil to cancer drugs, and there were questions for Novartis over the future of its struggling eyecare business. This week, Pfizer will update shareholders on plans for a potential break-up, while GlaxoSmithKline is likely to be pressed…
Chinese researcher in ‘economic warfare’ case loses appeal
This content was published on
A Chinese scientist, accused by the US of helping to steal trade secrets, must remain in Swiss custody due to flight risk, says a federal court.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.